Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.53 |
| ▸ | RXRB | P28702 | 6/20 | 0.53 |
| ▸ | RXRG | P48443 | 5/20 | 0.53 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.50 |
| ▸ | RARA | P10276 | 3/20 | 0.44 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | RARG | P13631 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176733 | 0.82 | RXRA (0.54) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2095481 | 0.80 | RXRA (0.57) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL694638 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL1616186 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL12743622 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2312146 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL14286073 | 0.80 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2897524 | 0.78 | CYP26B1 (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL16998630 | 0.77 | CYP26B1 (0.51) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL4440994 | 0.77 | RARA (0.56) | RXRARXRBRXRGCYP26B1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2061760-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-5688817-A | SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, IMMUNOLOGY AND RHEUMATIC DISORDERS | CENTRE INT'L. DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1997-11-18 | — | — | US | disclosed |
| US-5668156-A | TREATMENT OF WARTS, ACNE, PSORIASIS, CORNEOPATHIES, KETONES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-09-16 | — | — | US | disclosed |
| US-5597839-A | TREATMENT OF SKIN DISORDERS OR ANTIINFLAMMATORY AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1997-01-28 | — | — | US | disclosed |
| US-5567721-A | AROMATIC UREA COMPOUND FOR SKIN DISORDER, RHEUMATIC DISEASE, RESPIRATORY DISORDER AND EYE DISORDER | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1996-10-22 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
| EP-0552282-B1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CIRD GALDERMA (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0552282-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS. | CIRD GALDERMA (FR) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992006948-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | RXRA 311/4885RXRB 329/4885RXRG 222/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | RXRA 150/4885RXRB 211/4885RXRG 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.